The venom of snakes of the genus Pseudonaja contains prothrombin activators which initiate unchecked procoagulation in human (and canine) blood. This process is recognised clinically as disseminated intravascular coagulation (DIC)-it exhausts the supply of circulating coagulation factors and exposes the envenomated victim to the risk of spontaneous haemorrhage, perhaps a cerebral haemorrhage. In addition, uncontrolled coagulation may obstruct small calibre blood vessels which could cause ischaemia in vital tissue, including the myocardium.
The treatment of snake envenomation is of course the administration of antivenom-equine-derived antibodies which are assumed to bind and activate the numerous components of snake venom including its prothrombin activators. However, antivenom per se does not restore plasma coagulation factor levelsinstead it merely allows newly produced hepatic coagulation factors to accumulate in the blood without attack by prothrombin activators. The administration of exogenous coagulation factors, in the form of fresh frozen plasma (FFP), can restore normal coagulation in the intervening time of many hours before endogenous factors are produced. On the other hand, such factors could promote further intravascular coagulation if they encounter un-neutralized prothrombin activator.
Clinicians treating Brown Snake and other Australian snake bites, including Tiger Snakes and Taipans, are thus faced with a dilemma. Should they administer FFP to the victim after antivenom treatment in the hope of preventing a spontaneous haemorrhage but in doing so potentially expose the victim to further intravascular coagulation? The obvious answer to this problem would be to withhold FFP until all prothrombin activator in blood was neutralized. Unfortunately, there is no practical clinical way of ascertaining the blood levels of prothrombin activators. It is this dilemma that the study by Jelinek et al in this issue of the Journal attempted to resolve 1 . What harm can be done by administration of FFP to the envenomated victim? The investigators chose to investigate in a canine model of envenomation, but unfortunately the study has several methodological flaws.
The study involved a small number of animals (11 in total) divided into four groups: receiving one of two doses of antivenom ("adequate" or "inadequate") and either FFP or no FFP (adequate anti-venom+FFP 4 animals; adequate antivenom, no FFP 3 animals; inadequate antivenom+FFP 2 animals; inadequate antivenom, no FFP 2 animals). The two dogs which died had received FFP but neither of these two dogs had post mortems. Other dogs, not included in experimentation results, and which had received ten times larger doses of intravenous venom, but no FFP or antivenom, died immediately and in these, clots were observed in their cardiac chambers. From these observations, the investigators suggested that FFP was associated with death by massive intravascular clotting. This is not justifiable. The study had insufficient numbers. Indeed a Fishers exact test (Stata) returns a P value of 0.45 when animals with all does of antivenom are lumped, and a value of 1.00 when only inadequate doses of antivenom are considered. In other words, the result may have been due to chance.
Few decisions in management of envenomation are supported by high level evidence in humans. The use of adrenaline to prevent adverse reactions to antivenom is an exception 2 . Most evidence emanates from animal studies or human case reports or series. The study in this issue of the Journal is in the former category but it does not replicate human envenomation. Snake envenomation is usually subcutaneous, not intravenous. The experimenters attempted to create an animal model of human envenomation but they found that subcutaneous injection of venom in anaesthetized animals did not cause coagulopathy, and abandoned this mode of envenomation. Since venom gains access to the circulation by lymphatic channels, the immobile state caused by anaesthesia was probably responsible. However, human en-Fresh Frozen Plasma After Brown Snake Bite-Helpful or Harmful? Anaesth Intensive Care 2005; 33: [13] [14] [15] Editorial venomation can be simulated by manual exercise of the subcutaneously envenomated limb of the anaesthetized animal 3 .
Australian snake venoms have long been known to cause DIC after intravenous injection as demonstrated first by Martin in 1894 who experimented with Tiger Snake venom 4 . Venom-induced systemic hypotension was attributed to cor pulmonale by Feldberg and Kellaway in 1937, who experimented with Copperhead venom 5 , but those investigators made no connection with DIC. More recent experimentation with Brown Snake venom and one of its prothrombin activators recorded pari passu DIC, systemic hypotension and pulmonary hypertension [6] [7] [8] which could all be prevented by heparin 9 . Pulmonary thrombosis may be the cause for cor pulmonale and subsequent systemic hypotension. However, systemic hypotension may also be secondary to thrombotic myocardial ischaemia.
Do snake bite victims really die from DIC? Certainly, intra-cardiac clot formation has been observed by echocardiography in dog models of envenomation when venom has been injected intravenously 10 but no such clots have been observed post-mortem in human victims of envenomation. Even so, if they had been, there is an inherent difficulty differentiating postmortem clot formation from clots formed premortem-a problem which the Jelinek study model did not address. Echocardiography during FFP administration would allow differentiation of in vivo clot formation from post-mortem formation. Post mortem examination cannot differentiate easily.
One way of resolving the dilemma of whether to give FFP is to examine the mode of death in victims of Brown Snake envenomation. Unfortunately, only a few cases reported in sufficient detail permit analysis: cerebral haemorrhage was responsible for death in at least six cases [11] [12] [13] [14] [15] and cerebral infarction not associated with hypotension or hypoxaemia in one 16 . Notably, of the victims who died from cerebral haemorrhage, none had preceding haemorrhage elsewhere. Another clinician opined that several of these victims may have died because FFP was withheld 17 . Intra-cardiac thrombosis has not been reported in any case reports but it may not have been sought. Some case reports of Brown Snake envenomation suggest, as in animal experiments, that thrombotic myocardial ischaemia caused by thrombosis may occur 18 . If this is true, administration of FFP without adequate venom neutralization would be hazardous.
What should the clinician do? Although it may be acceptable for a patient who is not haemorrhaging to withhold FFP and to await spontaneous regeneration of clotting factors, this is not logical in the face of active haemorrhage. FFP should be administered after a neutralizing dose of antivenom-but therein lies another problem: the neutralization dose of antivenom in a clinical situation is unknown. Experiments in dogs 19 and in vitro with human plasma 20 showed that the neutralizing dose of antivenom for Brown Snake enveno-mation was many times higher than hitherto recommended. Recent clinical reports of envenomation have suggested that that many doses of antivenom may be needed 15 .
Although the study by Jelinek et al 1 raises an important and intriguing subject, its results do not permit adoption of its suggestions without further and more extensive experimentation in animals and documentation of human experience -assuming no controlled trial in humans is practical. A trial in humans is needed to resolve this problem, or in lieu of such trial, robust realistic animal experimentation simulating human envenomation designed to test the efficacy of FFP after adequate venom neutralization.
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